Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36972022

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2023 Jun 8
First author
Eskander RN

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2023 Jun;20(6):353. doi: 10.1038/s41571-023-00763-0.
    note
    Source null
    related pmid
    37024681
    relationship
    Comment in
  2. citation
    N Engl J Med. 2023 Aug 31;389(9):866. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646693
    relationship
    Comment in
  3. citation
    N Engl J Med. 2023 Aug 31;389(9):866-867. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646694
    relationship
    Comment in
  4. citation
    N Engl J Med. 2023 Aug 31;389(9):867. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646695
    relationship
    Comment in
  5. citation
    N Engl J Med. 2023 Aug 31;389(9):867-868. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646696
    relationship
    Comment in
  6. citation
    CA Cancer J Clin. 2023 Sep-Oct;73(5):445-447. doi: 10.3322/caac.21809.
    note
    Source null
    related pmid
    37665330
    relationship
    Comment in
  7. citation
    Transl Cancer Res. 2023 Oct 31;12(10):2438-2441. doi: 10.21037/tcr-23-1343.
    note
    Source null
    related pmid
    37969375
    relationship
    Comment in

Authors and identifiers

  1. name
    Eskander RN
    type
    Author
  2. name
    Sill MW
    type
    Author
  3. name
    Beffa L
    type
    Author
  4. name
    Moore RG
    type
    Author
  5. name
    Hope JM
    type
    Author
  6. name
    Musa FB
    type
    Author
  7. name
    Mannel R
    type
    Author
  8. name
    Shahin MS
    type
    Author
  9. name
    Cantuaria GH
    type
    Author
  10. name
    Girda E
    type
    Author
  11. name
    Mathews C
    type
    Author
  12. name
    Kavecansky J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Eskander RN
    type
    Author
  2. name
    Sill MW
    type
    Author
  3. name
    Beffa L
    type
    Author
  4. name
    Moore RG
    type
    Author
  5. name
    Hope JM
    type
    Author
  6. name
    Musa FB
    type
    Author
  7. name
    Mannel R
    type
    Author
  8. name
    Shahin MS
    type
    Author
  9. name
    Cantuaria GH
    type
    Author
  10. name
    Girda E
    type
    Author
  11. name
    Mathews C
    type
    Author
  12. name
    Kavecansky J
    type
    Author
bibliography ids
  1. nci-bib-3534ea7bbef078a5e2a6b311
book metadata
content sha256
39d14f20844e4605d6fcdbf149b0d4ee131eeee5df4b7150d17f490ee3bdca77
document type
citation
dois
  1. 10.1056/NEJMoa2302312
electronic publication date
display
2023 Mar 27
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:36972022
immutable id
pubmed:36972022@39d14f20844e4605d6fcdbf149b0d4ee131eeee5df4b7150d17f490ee3bdca77
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
23
name
The New England journal of medicine
nlm unique id
0255562
pages
2159-2170
volume
388
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2023 Jun;20(6):353. doi: 10.1038/s41571-023-00763-0.
    note
    Source null
    related pmid
    37024681
    relationship
    Comment in
  2. citation
    N Engl J Med. 2023 Aug 31;389(9):866. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646693
    relationship
    Comment in
  3. citation
    N Engl J Med. 2023 Aug 31;389(9):866-867. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646694
    relationship
    Comment in
  4. citation
    N Engl J Med. 2023 Aug 31;389(9):867. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646695
    relationship
    Comment in
  5. citation
    N Engl J Med. 2023 Aug 31;389(9):867-868. doi: 10.1056/NEJMc2308037.
    note
    Source null
    related pmid
    37646696
    relationship
    Comment in
  6. citation
    CA Cancer J Clin. 2023 Sep-Oct;73(5):445-447. doi: 10.3322/caac.21809.
    note
    Source null
    related pmid
    37665330
    relationship
    Comment in
  7. citation
    Transl Cancer Res. 2023 Oct 31;12(10):2438-2441. doi: 10.21037/tcr-23-1343.
    note
    Source null
    related pmid
    37969375
    relationship
    Comment in
outcomes validated
false
pmid
36972022
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
ba98b6eb6e29953579872bf69ffa1daf9ba5aa674a6e0547b99bbb78af98cb7c
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Jun 8
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, U.S. Gov't, P.H.S.
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36972022/
title
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

Preserved source evidence · Not medical advice